The US Labor Department reported that employers added 165,000 jobs in October, significantly surpassing the expected 59,000. Despite this strong job growth, the unemployment rate remained stable in the low 4% range, indicating a tight labor market. With employment trends steady, the Federal Reserve is expected to focus on inflation concerns when deciding on interest rates in December, with a likely rate increase by year-end.
The October US jobs report showed employers added 165,000 jobs, well above expectations, with unemployment steady near 4%. For readers following US stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:21 WIB: out of 150 priced US stocks, 60 rose and 85 fell. Notable movers include UMC at USD 14.59 (+9.04%), AMAT at USD 346.71 (+8.60%), and AMD at USD 438.73 (+8.49%), with typical hold times ranging from 44 to 93 days and mixed Pluang order activity percentages.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
